What makes our SteriPlas safe and effective?

What makes our SteriPlas Premium Cold Plasma safe and effective?

 

Adtec has been the global leader of Cold Plasma medicine, having developed Cold Plasma products for over 20 years and being the first company worldwide to conduct clinical trials on wounds. In total, Adtec boasts over 80+ clinical trials and studies with no side effects reported.

 

Whilst there are many forms of Cold Plasmas on the market, our SteriPlas Cold Plasma is dense and slowly propelled towards the treatment site enabling bacterial destruction in deep and hard to reach infection areas. The argon Cold Plasma is microwave, 2.45GHz generated using crucial components within the body of the medical device. This is why it is larger in size but at the advantage of delivering reliable and consistent results and easily tackles complicated biofilm issues within chronic infections unlike the other variations of Cold Plasma on the market. This is also why our clinical evidence is often cited by other Cold Plasma manufacturers as our promising results far outweigh the results achieved by Cold Plasma devices with different plasma designs.

 

To learn more about our strengths and benefits, contact us at info@adtecplasma.com


Leading the way in Cold Plasma Medicine

The antibiofilm properties of the SteriPlas has been widely documented across our 80+ clinical trials and studies. It is being widely used to treat a multitude of infection conditions such as Diabetic Foot Ulcers, Sternal Wounds and LVAD infections in the UK, EU and SE Asia. Helping to significantly reduce morbidity, mortality, amputation and bed occupancy rates, the SteriPlas has been transforming modern medicine by simplifying and accelerating the way these chronic and non-healing wounds are treated. We have also documented the significant cost saving benefits of using the SteriPlas Premium Cold Plasma all with the added benefit of no side effects due to its safe, microwave 2.45GHz argon plasma generation.

 

To learn more about the benefits we can bring you, contact us at info@adtecplasma.com


Upcoming Exhibitions for 2024

   

Adtec looks forward to exhibiting at the Diabetic Foot Study Group (DFSG) conference between 6-8 September and the European Mechanical Support Summit (EUMS) conference between 11-14 September. At both conferences, we will have our SteriPlas Premium Cold Plasma medical device on our booth for a live demonstration. The SteriPlas boasts a strong clinical evidence collection of 80+ clinical trials and studies across a multitude of infection conditions.

To better understand our medical device and the positive imprint we have made on the severe infection conditions, please visit our booth during the two shows to see the SteriPlas in person.


Day 2 of the Malvern Diabetic Foot Conference

Day 2 of the Malvern Diabetic Foot Conference 2024. Don't forget to visit us to see how Premium Cold Plasma SteriPlas has healed chronic diabetic foot ulcers.


Day 2 of EWMA 2024

Day 2 of the European Wound Management Association (EWMA) exhibition. Visit us at booth G70 to see our Premium Cold Plasma live in action. With the strongest clinical efficacy for the infection management in wounds, surgical site infections and medical dermatology.


Day 1 of EWMA 2024

Day 1 of the European Wound Management Association (EWMA) exhibition. We have enjoyed catching up with friends and meeting new people interested in our Premium Cold Plasma medical device. Our Clinical Bibliography of 80+ clinical trials and studies puts us at the forefront of Cold Plasma Medicine for wounds, surgical site infections and medical dermatology. Visit us at booth G70 to learn more.


EWMA 2024

We look forward to exhibiting at the European Wound Management Association (EWMA) exhibition next week. Positioned at booth #G70, our Premium Cold Plasma medical device, the SteriPlas, will be featured to the public. Adtec Healthcare Cold Plasma company can boast of having very strong clinical trials data amongst a total of 80+ peer reviewed studies. Our medical device has proven anti-biofilm efficacy in chronic infections within wounds, surgical site infections and medical dermatology conditions.


Day 1 of the ISHLT

An exciting start to the ISHLT 2024 show. Our SteriPlas Premium Cold Plasma medical device is being widely spoken about throughout the sessions and we welcome you to visit our booth no.12 to learn more.


Adtec to exhibit at the ISHLT show

We are excited to be exhibiting at the ISHLT show next week. Our team will be onsite at booth no. 12 ready to welcome you and introduce you to our SteriPlas Premium Cold Plasma medical device used for the treatment of LVAD infections complicated with biofilm. Many of our customers will also be at the show who would be happy to give you a demonstration of our SteriPlas or to explain the strong clinical efficacy observed when using our medical device.

If you would like to secure a meeting in advance, please contact us at info@adtecplasma.com

 


Adtec joins the Innovation Platform at LSI 2024

We look forward to participating at the Innovation Platform at the @LSI USA 2024. Our CEO, Mary McGovern, will be in the Private Partnering Area between 18-22 March 2024 meeting with exclusive Medtech and Healthtech leaders to bring the rich content of the SteriPlas Premium Cold Plasma to them.

 

The SteriPlas is renowned for its proven clinical efficacy destroying chronic and complicated biofilm within infected wounds and surgical site infections. Our wide clinical bibliography of 80+ clinical trials and studies ranges from diabetic foot ulcers, LVAD infections, Sternal wound infections and so on.

Delivering a unique physical mode of action during treatment, the SteriPlas dense Cold Plasma ensures the total destruction of all bacterial species protected within biofilm which would otherwise have been resistant to antibiotics. Essentially, we are saving limbs !

We have documented the cost savings benefit due to be published this year across two separate papers focused on diabetic foot ulcers and sternal wound infections.

 

Our purpose of the LSI Innovation Platform attendance is to seek the potential of investment to help bring our medical device to new territories that have yet to benefit from what we can offer.
Cold Plasma is changing the norm of modern medicine.